+40 264 433427

ORIGINAL PAPER

Genetic Variants in Nicotinamide-N-Methyltransferase (NNMT) Gene are Related to the Stage of Non-Alcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter (CAP)-FibroScan

 download Full Article (PDF file)

Eman M. Hasan1, Rasha A. Abd Al Aziz1, Dina Sabry2, Samar K. Darweesh1, Hedy A. Badary1, Aisha Elsharkawy1, Mahmood M. Abouelkhair 1, Ayman Yosry1

1) Hepato-Gastroenterology and Endemic Medicine Department,
2) Medical Biochemistry Department, Faculty of Medicine, Cairo University, Cairo, Egypt

DOI: http://dx.doi.org/10.15403/jgld.2014.1121.273.wsh

ABSTRACT
Background & Aims: Various genetic polymorphisms play a key-role in the pathogenesis of NAFLD and progression to NASH with fibrosis to cirrhosis. We aimed to study the association between single-nucleotide polymorphisms (SNPs) in NNMT gene, namely rs694539 and the development of different stages of NAFLD diagnosed by controlled attenuation parameter (CAP) of FibroScan Echosens®.

Methods: Transient elastography (FibroScan®) with controlled attenuation parameter (CAP) measurement was performed in 81 NAFLD patients (35 of them with liver biopsy) and 80 non-NAFLD controls. The accuracy of CAP and FibroScan for the detection and quantification of hepatic steatosis/fibrosis, respectively, was assessed based on liver biopsy aspect. Genetic variants of NNMT gene rs694539 were analyzed using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Results: According to BMI (kg/m2), among the patients, 17 (21%) were overweight, 56 (69.1%) obese, and 8 (9.9%) morbidly obese. CAP and FibroScan diagnosed steatosis/fibrosis correlated significantly with liver biopsy. There was a significant association between polymorphisms of rs694539-NNMT gene and NAFLD presence and stages. The mutant type (AA-genotype) was found in 33% NAFLD patients versus 1.2% controls (P<0.001), whereas the wild type (GG-genotype) was present in 21% versus 63.8% controls (P<0.001). Moreover, the AA-genotype significantly correlated with the steatosis degree by CAP but not the fibrosis degree by FibroScan. Multivariate regression analysis of all the independent risk factors showed non-significant correlations with the degree of steatosis on CAP. However, by using a stepwise approach, waist circumference showed significance as an independent predictor of NAFLD.

Conclusions: Polymorphisms in rs694539-NNMT gene (mutant AA-genotype) could be a genetic risk factor for developing NAFLD and NASH (indicating susceptibility for progression and complications). Individuals with wild type (GG-genotype) are at less risk of NAFLD development. CAP and FibroScan efficiently diagnosed steatosis and fibrosis.

Key words: Non-alcoholic Fatty Liver Disease (NAFLD) − Non-alcoholic Steatohepatitis (NASH) − Nicotinamide-N-methyltransferase (NNMT) gene − Single Nucleotide Polymorphisms (SNPs) − Controlled attenuation parameter (CAP) − FibroScan.

Abbreviations: CAP: controlled attenuation parameter; FBG: fasting blood glucose; LSM: Liver stiffness measurement; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic Steatohepatitis; NNMT: Nicotinamide-N-methyltransferase; PCR-RFLP: Polymerase chain reaction-Restriction fragment length polymorphism; SNPs: Single Nucleotide Polymorphisms; TE: transient elastography; TG: triglycerides; T2DM: type 2 dabetes mellitus.